Navigation Links
Watson Third Quarter 2011 Net Revenue Climbs 23% to $1.1 Billion; Non-GAAP Diluted EPS of $1.09; GAAP Diluted EPS of $0.54
Date:11/1/2011

AAP net income attributable to common shareholders

$
8.1$
25.7$
.1$
.1Plus:Interest expense

24.421.469.161.7Interest income

(0.3)(0.3)(1.6)(1.0)Provision for income taxes

50.9(12.2)135.452.4Depreciation (includes accelerated depreciation)

23.625.172.376.4Amortization(1)

72.045.9204.0128.0EBITDA238.7105.6645.3483.6Adjusted for:Global supply chain initiative

2.36.710.723.2Acquisition and licensing charges

9.52.422.923.9Non-cash impairment charges

3.80.125.61.2Non-recurring (gains) losses

(5.1)-(12.2)(24.8)Legal settlements

-89.9-92.9Accretion income

(0.2)-(0.2)-Share-based compensation

9.26.425.417.4Adjusted EBITDA

$
258.2$
211.1$
717.5$
7.4(1) Includes amortization of excess purchase price on equity method investment.The following table presents a reconciliation of forecasted net income for the twelve months ending December 31, 2011 to non-GAAP net income and non-GAAP earnings per diluted share:Table 6Watson Pharmaceuticals, Inc.Reconciliation Table - Forecasted Non-GAAP Earnings per Diluted Share(Unaudited; in millions except per share amounts)Forecast for Twelve MonthsEnding December 31, 2011LowHighGAAP to Non-GAAP net income calculationGAAP net income$
252$
265Adjusted for:Amortization 340340Global supply chain initiative1717Acquisition and licensing charges 2929Interest accretion on contingent liability 4141Non-cash impairment charges 2626Non-recurring (gains) losses (12)(12)Income taxes on items above(117)(117)Non-GAAP net income$
576$
589Diluted earnings per shareDiluted earnings per share - GAAP $
.99$
2.09Diluted earnings per share - Non-GAAP$
4.55$
4.65Diluted weighted average common shares outstanding126.6126.6The reconciliation table is based in part on management's estimate of non-GAAP net income for the year ending December 31, 2011.  Watson expects certain known GAAP charges for 2011, as presented in the
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
2. Watson to Present at the 2011 Annual Credit Suisse Health Care Conference
3. Watson Confirms Daytrana(R) Patent Challenge
4. Watson Provides Update on District Court Order Concerning Generic Version of LOVENOX®
5. Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R)
6. Watson Confirms EMBEDA(R) Patent Challenge
7. Watson Launches Generic FEMCON(R) Fe
8. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings
9. Watson to Present at the Jefferies 2011 Global Healthcare Conference
10. Watson Confirms Amphastar Patent Lawsuit
11. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015  Astellas announced that two ... one abstract detailing clinical data from a study of ... presented during a late breaking plenary session at the ... on May 17 in New Orleans, Louisiana ... Phase 2 studies designed to evaluate enzalutamide compared to ...
(Date:5/5/2015)... MINNEAPOLIS , May 5, 2015 Bio-Techne ... of Directors has decided to pay a dividend of ... 2015. The quarterly dividend will be payable May 29, ... 15, 2015.  Future cash dividends will be considered by ... Bio-Techne Corporation (NASDAQ: TECH ) is a ...
(Date:5/5/2015)... -- - No one has covered cath ... ABMRG - Primary research covering 700 angioplasty ... among states & regions; hospital chains; govt. & pvt. ... coronary stent market in India , ... (BMS) and Bio-Absorbable Stent (BVS), was valued above $400 ...
Breaking Medicine Technology:Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 2Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 3Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 4Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 5Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 6Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 7Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 8Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 9India Coronary Stent Market to be Tripled by 2021 2India Coronary Stent Market to be Tripled by 2021 3India Coronary Stent Market to be Tripled by 2021 4
... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced ... on Tuesday, May 8, 2012 at 4:30 p.m. EDT/9:30 p.m. ... and financial update and review first quarter 2012 results. ... from the Investors section of the Jazz Pharmaceuticals website at ...
... IRVINE, Calif., April 30, 2012  PRO-DEX, INC. (Nasdaq: ... in management,s broadcast review of the Company,s fiscal 2012 ... ) The conference call is scheduled ... May 4, 2012 at 4:30 p.m. Eastern Time (1:30 ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast 2
(Date:5/5/2015)... " QuickPick Travel ” was featured on NewsWatch as ... small, medium, and large businesses making an impact in their ... expert, conducted the business review and shared with viewers how ... weeks of vacation for free. , Vacations are a sought-after ... world. And when people are preparing for vacations, they’re used ...
(Date:5/5/2015)... This year, PolyU researchers garnered two ... Awards, three Gold Medals and four Silver Medals at ... follows: , (1) Grand Prize and Gold Medal with ... Design and Fitting, Principal Investigator: Dr Allan Chee-kooi CHAN, ... relies very much on the “mannequin” for many tasks ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 ... mission-focused company serving the federal government, today announced ... (CCSi). CCSi provides solutions exclusively to federal ... extensive experience in cyber security, health services, and ... processes and industry-relevant credentials as a Third Party ...
(Date:5/5/2015)... The brains of people with type ... with slower information processing, according to research led by ... Health . , The findings indicate that clinicians ... for cognitive difficulties. If progressive, these changes could influence ... by the National Institutes of Health (NIH), ...
(Date:5/5/2015)... Washington, DC (PRWEB) May 05, 2015 ... Amplify Hope Initiative, a new study aimed at determining ... disease patients. RG is an international non-profit providing rare ... genomics sequencing technology, connections to scientists and researchers, and ... or crowdfunding. , “I am excited to see how ...
Breaking Medicine News(10 mins):Health News:A Platform to Plan the Perfect Vacation was Featured on NewsWatch Television 2Health News:PolyU wins top prizes in Geneva’s Invention Expo 2Health News:PolyU wins top prizes in Geneva’s Invention Expo 3Health News:PolyU wins top prizes in Geneva’s Invention Expo 4Health News:PolyU wins top prizes in Geneva’s Invention Expo 5Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4Health News:Accelerated Brain Aging in Type 1 Diabetes Related to Cognitive Complications 2Health News:Accelerated Brain Aging in Type 1 Diabetes Related to Cognitive Complications 3Health News:Accelerated Brain Aging in Type 1 Diabetes Related to Cognitive Complications 4Health News:Rare Genomics Institute to Study Impact of Crowdfunding on Rare Diseases 2
... New research released to mark No Smoking Day (11 March) ... in Great Britain are thinking,about or planning to cut down or ... shows that one in ten (9%) will be taking the first,step ... No Smoking Day President and Dragons, Den star, ...
... , , TUESDAY, March 10 (HealthDay News) -- Used together, a ... in detecting ovarian cancer in its early and more curable ... become a new standard in the fight against this deadly ... to be an approach that may be workable," said Robert ...
... state budget maintains charity care spending levelMARLTON, N.J., March ... Virtua Health, praised New Jersey Governor Jon Corzine, Health ... for placing a high priority on the health care ... that was unveiled today in Trenton.In the state fiscal ...
... ARBOR, Mich.---Biomedical and materials engineers at the University ... brain implants that helps the devices operate longer ... epilepsy and Parkinson,s disease. , Currently, brain implants ... and the next generation of the devices operate ...
... A recent CBS 60 Minutes TV program drew ... molecule believed to largely be responsible for the ... more people living beyond 100 years and exhibit ... than other people living in other developed countries, ...
... people with peripheral arterial disease, study finds, , , ... arterial disease with drug-eluting stents may save lives ... Greek researchers have found. , Peripheral arterial disease ... leads to severe obstructions, known as critical limb ...
Cached Medicine News:Health News:Recession leads 1 in 3 Smokers to cut Down or Quit 2Health News:Recession leads 1 in 3 Smokers to cut Down or Quit 3Health News:Combo of Tests Might Spot Ovarian Cancer Early 2Health News:Combo of Tests Might Spot Ovarian Cancer Early 3Health News:Virtua Commends Gov. Corzine's Charity Care Funding Plan 2Health News:Nanotech coating could lead to better brain implants to treat diseases 2Health News:Researchers Report Combined Molecules in Red Wine by Far Exceed the Biological Activity of Plain Resveratrol, Consistent With the Composition of Longevinex(R) 2Health News:Researchers Report Combined Molecules in Red Wine by Far Exceed the Biological Activity of Plain Resveratrol, Consistent With the Composition of Longevinex(R) 3Health News:Drug-Eluting Stents Show Promise for Leg Arteries 2Health News:Drug-Eluting Stents Show Promise for Leg Arteries 3
The APR Hip System offers a complete line of stems to precisely match patients' anatomic needs and address surgeon preferences....
Classic proven design with superior clinical results....
The Perfecta PDA components provide the design and material choice imperative in today's cost conscious medical climate....
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
Medicine Products: